Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases

NCT03320538 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2024-07-03

No results posted yet for this study

Summary

This trial aims to determine whether Jiangzhong Hou Gu® Mi Xi™ is an effective intervention to improve symptoms and indicators in patients with spleen qi deficiency and peptic ulcer diseases.

Conditions

  • Peptic Ulcer Disease

Interventions

OTHER

Hou Gu Mi Xi

Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).

OTHER

Placebo

The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.

DRUG

Rabeprazole

Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.

Sponsors & Collaborators

  • Jiangxi Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN
  • The First Affiliated Hospital of Nanchang University

    collaborator OTHER
  • Second Affiliated Hospital of Nanchang University

    collaborator OTHER
  • The Third Affiliated Hospital of Nanchang University

    collaborator OTHER
  • Nanchang Hongdu Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN
  • Nanchang Hospital of Integrated Traditional Chinese and Western Medicine

    collaborator UNKNOWN
  • The Nanchang Third Hospital

    collaborator UNKNOWN
  • Xinyu People's Hospital

    collaborator UNKNOWN
  • Xinyu Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN
  • Jiujiang No.1 People's Hospital

    collaborator OTHER
  • Jiujiang Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN
  • Jiangxi University of Traditional Chinese Medicine

    lead OTHER

Principal Investigators

  • Weifeng Zhu, Ph.D. · Jiangxi University of Traditional Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-10
Primary Completion
2020-09-17
Completion
2020-09-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03320538 on ClinicalTrials.gov